Table 1.
R1R2N-CSS−M+ 1a-27a
| ||||||
---|---|---|---|---|---|---|
No*,# | R1 | R2 | KI (nM)# | |||
hCA I | hCA II | hCA IX | hCA XII | |||
1a | H | Ph | 4.8 | 4.5 | 4.2 | 4.3 |
2a | H | O[(CH2CH2)]2N | 4.8 | 3.6 | 29.1 | 9.2 |
3a | H | MeN[(CH2CH2)]2N | 33.5 | 33.0 | 22.1 | 17.5 |
4a | H | 2-butyl | 21.1 | 29.4 | 4.6 | 31.7 |
5a | H | O[(CH2CH2)]2N(CH2)2 | 31.8 | 36.3 | 4.5 | 4.2 |
6a | H | N[(CH2CH2)N]3 | 31.9 | 13.5 | 27.4 | 9.3 |
7a | H | PhCH2 | 4.1 | 0.70 | 19.2 | 11.5 |
8a | H | 4-PyridylCH2 | 3.5 | 16.6 | 26.0 | 24.1 |
9a | H | [(CH2)5N]CH2CH2 | 4.5 | 20.3 | 3.6 | 20.5 |
10a | H | 2-thiazolyl | 3.9 | 4.6 | 12.6 | 22.0 |
11a | H | KOOCCH2 | 13.1 | 325 | 57.1 | 6.7 |
12a | H | imidazol-1-yl-(CH2)3 | 8.6 | 24.7 | 4.3 | 6.5 |
13a | Me | Me | 699 | 6910 | 714 | 798 |
14a | Et | Et | 790 | 3100 | 1413 | 1105 |
15a | (CH2)5 | 0.96 | 27.5 | 70.4 | 46.1 | |
16a | iso-Bu | iso-Bu | 0.97 | 0.95 | 4.5 | 0.99 |
17a | n-Pr | n-Pr | 1838 | 55.5 | 53.8 | 7.0 |
18a | n-Bu | n-Bu | 43.1 | 50.9 | 50.3 | 5.8 |
19a | n-Hex | n-Hex | 48.0 | 51.3 | 27.4 | 16.1 |
20a | Et | n-Bu | 157 | 27.8 | 25.9 | 7.5 |
21a | HOCH2CH2 | HOCH2CH2 | 9.2 | 4.0 | 4.3 | 4.2 |
22a | Me | Ph | 39.6 | 21.5 | 28.2 | 7.7 |
23a | Me | PhCH2 | 69.9 | 25.4 | 53.0 | 3.0 |
24a | O[(CH2CH2)]2 | 0.88 | 0.95 | 6.2 | 3.4 | |
25a | NaS(S=C)N[(CH2CH2)]2 | 12.6 | 0.92 | 37.5 | 0.78 | |
26a | (NC)(Ph)C(CH2CH2)2 | 48.4 | 40.8 | 757 | 169 | |
27a | (S)-[CH2CH2CH2CH(COONa)] | 2.5 | 17.3 | 4.1 | 4.0 | |
AAZ | - | 250 | 12 | 25 | 5.7 |
Compounds 1a, 8a and 10a were thriethylamonium salts; 2a-6a, 9a, 11a and 12a were potasium salts, and the remaining ones were sodium salts.
Mean from 3 different assays. Errors were within ± 5–10 % of the reported values (data not shown).
Inhibition data against hCA I, II and IX for 9 DTCs, i.e. compounds 13a, 14a, 16–18a, 20a, 22a, 23a and 26a, were reported in ref.25